BNTC
NASDAQ HealthcareBenitec Biopharma Inc. - Common Stock
Biotechnology
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
๐ Market Data
| Price | $11.02 |
|---|---|
| Volume | 422,989 |
| Market Cap | 384.41M |
| Beta | 0.270 |
| RSI (14-Day) | 35.2 |
| 200-Day MA | $12.05 |
| 50-Day MA | $12.47 |
| 52-Week High | $16.76 |
| 52-Week Low | $9.85 |
| Forward P/E | -1.17 |
| Price / Book | 2.14 |
๐ฏ Investment Strategy Scores
BNTC scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (69/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (12/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find BNTC in your text
Paste any article, transcript, or post โ the tool will extract BNTC and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.